China CanSinoBIO's COVID-19 vaccine trials recruit over 20,000 people

BEIJING (Reuters) – China's CanSino Biologics Inc has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday.The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy.”As for now, the number of recruited participants has exceeded 20,000 people, and the progress is relatively fast,” said Zheng Zhongwei, an official at China's National Health Commission, told a press conference.Phase 3 trials for CanSinoBIO's candidate,…